Glancy Prongay & Murray LLP Commences Investigation on Behalf of PetMed Express, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf PetMed Express, Inc. (“PETMED” or
the “Company”) (NASDAQ: PETS) concerning the Company and its officers’ possible violations of federal securities laws. To obtain
information or aid in the investigation, please visit the PETMED investigation page on our website at www.glancylaw.com/case/petmed-express-inc.
On August 23, 2017, Aurelius Value published a report alleging that the Company targets opioid users with Google ads and other
marketing techniques to facilitate the abuse of opiates. On this news the Company’s shares fell significantly in value thereby
injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased PETMED securities, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at
310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of
shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170823005901/en/